Intravenous azithromycin-induced ototoxicity

Area of Science:

• Otolaryngology
• Infectious Diseases
• Pharmacology

Background:

• Intravenous azithromycin is a common treatment for hospitalized community-acquired pneumonia.
• Macrolide antibiotics, including azithromycin, are known to cause ototoxicity, particularly at high serum concentrations.
• Current intravenous dosing regimens may lead to higher azithromycin serum levels compared to oral administration.

Observation:

• A case study details a 47-year-old woman treated with intravenous azithromycin for community-acquired pneumonia.
• The patient received 8 days of intravenous azithromycin therapy.
• Following treatment, the patient experienced complete deafness.

Findings:

• The case suggests a potential link between intravenous azithromycin administration and severe ototoxicity.
• High serum concentrations of azithromycin, achievable with intravenous dosing, may be a contributing factor to hearing loss.
• This adverse event highlights a specific risk associated with current treatment protocols.

Implications:

• Healthcare providers should be aware of the ototoxicity risk associated with intravenous azithromycin.
• Further research is warranted to evaluate the safety and optimal dosing of intravenous azithromycin, especially in vulnerable patient populations.
• Consideration of alternative antibiotic regimens or closer monitoring for hearing impairment may be necessary in patients receiving prolonged intravenous azithromycin therapy.